NasdaqGS - Nasdaq Real Time Price USD

23andMe Holding Co. (ME)

0.4641

+0.0051

(+1.11%)

At close: April 26 at 4:00 PM EDT

0.4637

-0.00

(-0.09%)

After hours: April 26 at 7:39 PM EDT

7 Best Sites Like Ancestry.com to Research Your Family History

In this article, we take a look at 7 best sites like Ancestry.com to research your family history. If you would like to skip our detailed analysis of the genealogy industry, you can directly go to 3 Best Sites Like Ancestry.com to Research Your Family History. The Genealogy Industry Genealogy is the study of families, […]

Insider Monkey yesterday

ME
+1.11%
QGEN
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presentedSOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two abstracts on 23ME-00610, a first-in-class anti-CD200R1 antibody, have been accepted for poster presentations at the 2024 ASCO Annual Meeting, taking place May 31 - June 4 in Chicago. 23an

GlobeNewswire 2 days ago

ME
+1.11%
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next

Matterport is being acquired by a real estate giant, but it might not be the last ex-SPAC to go this route.

Motley Fool 3 days ago

ME
+1.11%
CSGP
23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid

In what looks like a potentially downbeat ending to 23andMe journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojcicki, who controls more than 20% of 23andMe’s stock, with about 49% voting control, told the company that she is considering making an offer to buy the shares she doesn’t already own. Neither Wojcicki nor the company have commented on what she might be willing to pay, but investors appear skeptical that it will come at a premium price.

Barrons.com 7 days ago

ME
+1.11%
Stocks to Watch Thursday: TSMC, Netflix, Nvidia, Tesla

↘️ **Taiwan Semiconductor Manufacturing (TSMC)**: TSMC reported its first profit rise in a year. However, the chip maker's American depositary receipts fell more than 3% after it cut its forecast for the overall semiconductor market, excluding the memory sector.

The Wall Street Journal 8 days ago

EFX

ME
+1.11%
HPGSF
23andMe Stock Jumps on News of Plans to Take It Private

Shares of 23andMe jumped Thursday on the news that the DNA-testing company's chief executive plans to take it private. 23andMe's stock was recently up nearly 35%. Anne Wojcicki's intentions were revealed in a late-Wednesday filing; read more about this story here.

The Wall Street Journal 8 days ago

ME
+1.11%
23andMe CEO Anne Wojcicki Plans to Take Company Private

The intentions, revealed in a public filing, come after the once-hot company’s share price closed at a new low and its enterprise value fell below zero.

The Wall Street Journal 8 days ago

ME
+1.11%
23andMe Jumps as CEO Floats Taking DNA Tester Private

(Bloomberg) -- DNA testing firm 23andMe Holding Co.’s shares soared after Chief Executive Officer Anne Wojcicki said she’s considering taking the struggling company private, less than three years after it began selling shares.Most Read from BloombergDubai Grinds to Standstill as Flooding Hits CityElon Wants His Money BackSingapore Loses ‘World’s Best Airport’ Crown to QatarRecord Rainfall in Dubai? Blame Climate Change, Not Cloud SeedingRed Lobster Considers Bankruptcy to Deal With Leases and La

Bloomberg 8 days ago

ME
+1.11%
23andMe announces CEO’s intention to pursue a potential take-private

SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E

GlobeNewswire 8 days ago

ME
+1.11%
23andMe CEO plans to take company private

Anne Wojcicki wants to buy all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

MedTech Dive 8 days ago

ME
+1.11%
23andMe CEO Wojcicki considering taking firm private, filing shows

Last week, Wojcicki notified members of the board's special committee that she is considering a potential go-private transaction for 23andMe and indicated that she would begin speaking to partners and financing sources. 23andMe declined to comment on the filing and Wojcicki did not immediately respond to a Reuters' request for comment. 23andMe, best known for its saliva-based test kits that offer users a glimpse into their genetic ancestry went public in 2021 through a blank-check firm, backed by Virgin Group founder Richard Branson, in a deal that valued the merged entity at $3.5 billion.

Reuters 9 days ago

ME
+1.11%
Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 9 days ago

ME
+1.11%
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, antibody targeting CD200R1: Preclinical data will be presented on targeting the CD200R1 pathway in T cells and natural killer cells using 23ME-00610 as a single agent, or in combination with other anti-tumor therapies SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (

GlobeNewswire 21 days ago

ME
+1.11%
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

Motley Fool last month

ME
+1.11%
GSK
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating

GlobeNewswire last month

ME
+1.11%
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migrationSOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for 23andMe+ Premium and Total Health members, that uncovers DNA connections to 335 unique historical individuals, from medieval Vikings to late Stone Ag

GlobeNewswire last month

ME
+1.11%
23andMe Launches New Genetic Reports on Common Forms of Cancer

23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMeSOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models know

GlobeNewswire last month

ME
+1.11%
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathwaySOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral presentation and two poster presentations on two of

GlobeNewswire last month

ME
+1.11%
20 Most Valuable Digital Health Companies In The US

In this article, we will be taking a look at the 20 most valuable digital health companies in the US. If you are not interested in reading about the global health market, head straight to the 5 Most Valuable Digital Health Companies In The US. As of the latest data, several digital health companies stand […]

Insider Monkey 2 months ago

TDOC

AMWL

WGSWW
Is 23andMe Stock a Smart Buy Right Now?

It's having trouble getting its core business model to work.

Motley Fool 2 months ago

ME
+1.11%

Performance Overview

Return	ME	S&P 500
YTD	-49.22%	+6.92%
1-Year	-76.44%	+25.26%
3-Year	-95.35%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

23andMe Holding Co. (ME)

7 Best Sites Like Ancestry.com to Research Your Family History

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next

23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid

Stocks to Watch Thursday: TSMC, Netflix, Nvidia, Tesla

23andMe Stock Jumps on News of Plans to Take It Private

23andMe CEO Anne Wojcicki Plans to Take Company Private

23andMe Jumps as CEO Floats Taking DNA Tester Private

23andMe announces CEO’s intention to pursue a potential take-private

23andMe CEO plans to take company private

23andMe CEO Wojcicki considering taking firm private, filing shows

Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

23andMe Launches New Genetic Reports on Common Forms of Cancer

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

20 Most Valuable Digital Health Companies In The US

Is 23andMe Stock a Smart Buy Right Now?

Performance Overview